

# Barbara Pistilli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6790491/publications.pdf>

Version: 2024-02-01

43  
papers

1,061  
citations

516710

16  
h-index

434195

31  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1551  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. <i>Annals of Oncology</i> , 2019, 30, 1784-1795.	1.2	138
2	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131
3	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. <i>Breast</i> , 2015, 24, 201-207.	2.2	97
4	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020, 38, 2762-2772.	1.6	80
5	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	1.6	70
6	Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. <i>European Journal of Cancer</i> , 2018, 95, 93-101.	2.8	50
7	Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002989.	8.4	47
8	Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 357-364.	2.5	46
9	Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021, 125, 1486-1493.	6.4	37
10	The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. <i>European Journal of Cancer</i> , 2016, 66, 131-137.	2.8	33
11	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017, 86, 257-265.	2.8	31
12	Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. <i>International Journal of Cancer</i> , 2019, 145, 3359-3369.	5.1	29
13	Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. <i>Breast</i> , 2020, 52, 50-57.	2.2	25
14	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 1111-1123.	1.6	23
15	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204.	1.6	23
16	Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1759-1766.	2.5	18
17	Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 501-509.	2.5	18
18	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2148-2162.	1.6	18

#	ARTICLE	IF	CITATIONS
19	Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). <i>ESMO Open</i> , 2021, 6, 100220.	4.5	15
20	Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 60-72.	3.8	15
21	Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 164, 70-79.	2.8	14
22	Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements. <i>Cancer</i> , 2021, 127, 2774-2787.	4.1	12
23	PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1105-TPS1105.	1.6	11
24	Determinants of use of oral complementary-alternative medicine among women with early breast cancer: A focus on cancer-related fatigue. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 517-529.	2.5	9
25	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021, 158, 169-180.	2.8	9
26	A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. <i>Trials</i> , 2022, 23, 193.	1.6	9
27	Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials. <i>Clinical Breast Cancer</i> , 2019, 19, 63-70.	2.4	8
28	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e575-e583.	2.4	7
29	Use of mHealth to Increase Physical Activity Among Breast Cancer Survivors With Fatigue: Qualitative Exploration. <i>JMIR Cancer</i> , 2021, 7, e23927.	2.4	6
30	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	3.2	5
31	Defining research priorities without biases: what is the optimal process?. <i>Annals of Oncology</i> , 2017, 28, 195-196.	1.2	4
32	Safety of bevacizumab in cancer patients with inflammatory bowel disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 664-664.	1.6	4
33	Real-world evidence of the management and prognosis of young women (≥1/240 years) with de novo metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110703.	3.2	4
34	Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 98-110.	4.9	3
35	Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. <i>Cancers</i> , 2022, 14, 2914.	3.7	3
36	Prognostic assessment and systemic treatments of invasive local relapses of hormone receptor-positive breast cancer. <i>Breast</i> , 2017, 35, 162-168.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program. <i>Annals of Oncology</i> , 2018, 29, viii710.	1.2	2
38	Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. <i>Breast</i> , 2021, 57, 43-48.	2.2	2
39	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. <i>JAMA Oncology</i> , 2021, 7, 1573-1574.	7.1	1
40	Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. <i>European Journal of Cancer</i> , 2021, 156, 217-221.	2.8	1
41	Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592098054.	3.2	1
42	Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care. <i>Annals of Oncology</i> , 2021, 32, 1206-1208.	1.2	0
43	Impact of Systemic Anticancer Therapy on Fertility. , 2020, , 67-80.		0